Pulmonary hypertension (PH) can be challenging for healthcare professionals to diagnose because of its vague symptoms, such as fatigue and shortness of breath. These symptoms, which may be mild ...

PAH is a life-threatening disease, caused by the narrowing of blood vessels in the lungs, which is currently treated mainly with drugs that dilate the blood vessels, like endothelin antagonists ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

In PAH, 'living better' is quantified by such measures ... This strategy is favored by the reduction in unnecessary drug exposure and costs, although this may be outweighed by increased overall ...

Current drugs available for the treatment of primary arterial hypertension (PAH) do not markedly improve survival and novel therapeutic strategies are required. Bone morphogenetic protein receptor ...

The follow-up study ZENITH has now also demonstrated the benefits of the drug in patients with advanced PAH with a high risk of dying within a year. Prof. Dr. Marius Hoeper, Acting Director of the ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...